VER-01 offers an investigational approach distinct from traditional treatment paradigms.
VERTANICAL is undertaking a pivotal Phase III US trial for future FDA submission. Credit: Gorodenkoff / Shutterstock.com.
VERTANICAL has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for VER-01, its investigational non-opioid treatment for chronic low back pain.
The designation follows two randomised, controlled Phase III trials that showed significant pain reduction, good tolerability, and no evidence of dependence. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
